|1.||Zeuzem, Stefan: 39 articles (12/2015 - 10/2002)|
|2.||Soriano, Vincent: 39 articles (01/2015 - 05/2003)|
|3.||Deeks, Steven G: 37 articles (06/2015 - 02/2002)|
|4.||Kumada, Hiromitsu: 30 articles (10/2015 - 01/2003)|
|5.||Chinnaiyan, Arul M: 30 articles (09/2015 - 11/2002)|
|6.||Zhang, Wei: 29 articles (01/2016 - 04/2002)|
|7.||Busch, Michael P: 28 articles (10/2013 - 05/2002)|
|8.||Thornton, Charles A: 27 articles (10/2014 - 07/2002)|
|9.||Wedemeyer, Heiner: 26 articles (12/2015 - 12/2006)|
|10.||Suzuki, Fumitaka: 26 articles (10/2015 - 01/2003)|
02/01/2015 - "Pharmacologically inhibiting the glycolytic pathway dramatically reduced DENV RNA synthesis and infectious virion production, revealing a requirement for glycolysis during DENV infection. "
01/01/2003 - "Extremely high agreement was found between the results of ELISA and qualitative detection of HCV-RNA, using a RT-PCR test as a gold standard for the diagnosis of HCV infection. "
02/01/1998 - "The lowest baseline serum HCV RNA concentration was observed in patients with genotype 2 infection and the greatest decrease in HCV RNA from baseline to month 1 in those with genotype 3. The findings suggest that measuring HCV RNA in serum before and soon after beginning treatment can be helpful for selecting patients who are most likely to have a sustained complete response to standard schedule of alpha-IFN and for identifying patients in whom alternative strategies should be examined."
01/01/1985 - "Both subcutaneous and intraperitoneal, but not intravenous administration of fraction I, fraction II, or purified RNA induced significant protection against intraperitoneal infection, the intraperitoneal route of administration being the most effective. "
07/01/2008 - "Taken together, these findings suggest that the Dz molecule can be used as selective and effective inhibitor of HCV RNA replication, which can be explored further for development of a potent therapeutic agent against HCV infection."
08/01/2011 - "Small interfering RNAs (siRNAs) are small RNA molecules that have a potent, sequence-specific gene silencing effect and therefore show promise for therapeutic use as molecular-targeted drugs for the treatment of various genetic diseases, including cancer. "
08/01/2011 - "Our data support the role of tumor-derived TNF-α expression as an important promoter of tumoral immune escape mechanisms and malignant progression, and suggest that analysis on either protein (immunohistochemistry) or RNA level (RT-PCR) can be used effectively in this respect. "
01/01/2010 - "Our data support the role of tumor-derived TNF-α expression as an important promoter of tumoral immune escape mechanisms and malignant progression, and suggest that analysis on either protein (immunohistochemistry) or RNA level (RT-PCR) can be used effectively in this respect. "
01/01/2008 - "We conclude that electroporation with whole tumor cell RNA and pulsing with UV-irradiated tumor cells are both effective in eliciting antitumor immune response, but RNA electroporation results in more potent tumor vaccination under the examined experimental conditions."
11/01/2003 - "PC3 tumor cells had transiently increased RNA at 12 hours with a marked decrease at 48 hours. "
|3.||Chronic Hepatitis C
03/28/2010 - "Short-term PEG-IFN alpha2a monotherapy is highly effective for chronic hepatitis C patients who have low pretreatment HCV RNA load and exhibit IVR."
09/01/2007 - "There is a tendency to individualize treatment in chronic hepatitis C patients depending on viral load and rapid clearance of HCV-RNA. "
01/01/2006 - "Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load."
07/01/2005 - "RIB administration preceding combined treatment of RIB with IFN was more effective in Th2 cell expansion than the usual combined treatment of IFN with RIB and led to a relatively early virological clearance in chronic hepatitis C patients with genotype 1b and a high HCV RNA level."
08/01/2000 - "The twice-a-day administration of IFN accelerated the clearance of HCV RNA from serum, leading to a more efficient virological response for patients with chronic hepatitis C, but with a high rate of renal toxicity."
07/01/1994 - "This study reveal that IFN therapy for acute hepatitis C may contribute to prevent the progression to chronicity and that the determination of the level of serum HCV RNA, HCV genotypes and anti C 100-3 levels may be useful to predict that efficacy of IFN and also to make a schedule for successful IFN therapy."
01/01/1999 - "In conclusion, the search for HCV RNA by RT-PCR within the liver biopsy specimen can establish rapid and unequivocal diagnosis of hepatitis C in at least 60% of anti-HCV antibody-positive patients who are seronegative for HCV RNA, and thus may help to avoid repeated testing and delayed therapy. "
04/01/2013 - "Accurate hepatitis C virus (HCV) RNA quantification is mandatory for the management of chronic hepatitis C therapy. "
01/01/2012 - "The gold standard for the diagnosis of acute hepatitis C is demonstration of conversion to anti-HCV positivity, HCV RNA positivity or both, events that frequently occur before the patient comes to medical attention. "
11/01/2009 - "The gold standard for the diagnosis of acute hepatitis C (AHC) is seroconversion to anti-HCV/HCV-RNA positivity, an occurrence frequently missed in clinical practice. "
09/01/2004 - "On the other hand, the pp67 RNA assay was highly specific and effective in pinpointing high viremia patients. "
08/01/2003 - "Nevertheless, from a viral perspective, the patient most likely to achieve a good outcome following OLT is someone with low-level (< or = 10(9) copies/mL) HCV RNA viremia both pre- and post-OLT and a genotype other than lb. "
01/01/2002 - "A rapid and marked decrease of HCV RNA viremia of more than 2 logs was observed in 10 (71%) of 14 patients at week 2 of treatment. "
08/01/2001 - "HBV/HCV coinfection was associated with lower HBV viremia (8.2 x 10(4) copies/mL) and lower HCV-RNA levels (7 x 10(5) IU/mL), than the corresponding control group (P <.05), with more marked decrease in HBV replication (P <.05). "
06/27/2006 - "DFPP appeared to be effective in reducing HCV viremia and preventing HCV recurrence in patients with high HCV RNA levels after LDLT. "
|1.||DNA (Deoxyribonucleic Acid)
|3.||Interferon-alpha (Interferon Alfa)
|5.||Messenger RNA (mRNA)
|7.||RNA (Ribonucleic Acid)
|9.||Alanine Transaminase (SGPT)
|10.||Immunoglobulin M (IgM)
|1.||Drug Therapy (Chemotherapy)
|4.||Transplantation (Transplant Recipients)
|5.||Highly Active Antiretroviral Therapy (HAART)